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Abstract: As laser refractive surgeries (LRS) have been widely performed to correct myopia, ophthal-
mologists easily encounter patients with glaucoma who have a history of LRS. It is well known that
intraocular pressure (IOP) in eyes with glaucoma is not accurate when measured using Goldmann
applanation tonometry. However, risk factors for glaucoma progression, particularly those associated
with measured IOP, have rarely been studied. We analysed data for 40 patients with a history of
LRS and 50 age-matched patients without a history of LRS. Structural progression was defined as
significant changes in thickness in the peripapillary retinal nerve fibre layer as identified using optical
coherence tomography event-based guided progression analysis. Risk factors were determined via
Cox regression analysis. Disc haemorrhage (DH) was associated with glaucoma progression in both
the non-LRS group and LRS group (hazard ratio (HR): 4.650, p = 0.012 and HR: 8.666, p = 0.019,
respectively). However, IOP fluctuation was associated with glaucoma progression only in the LRS
group (HR: 1.452, p = 0.023). Our results show that DH was a significant sign of progression in
myopic glaucoma eyes. When treating patients with myopia and glaucoma, IOP fluctuation should
be monitored more carefully, even if IOP seems to be well controlled.
Keywords: glaucoma; myopia; laser refractive surgery; intraocular pressure; disc haemorrhage;
optical coherence tomography; Goldmann applanation tonometry; LASIK; LASEK
1. Introduction
Laser refractive surgeries (LRSs), such as photorefractive keratectomy, laser in situ
keratomileusis (LASIK), and laser in situ epithelial keratomileusis (LASEK), are widely
performed to correct myopia. Since myopia is a well-known risk factor for glaucoma [1,2],
ophthalmologists commonly encounter patients with glaucoma who have a history of
LRS or are planning to undergo LRS. Patients with glaucoma often have some concerns
regarding the effects of LRS on the development or progression of glaucoma.
Several studies have investigated whether LRS exacerbates glaucomatous damage
or aggravates glaucoma progression. Acute increases in intraocular pressure (IOP) can
damage the optic nerve during surgical procedures [3], and studies have also reported
that topical steroid use can cause postoperative increases in IOP [4,5]. Another concern
is the reliability of IOP measurements after LRS. Since IOP is the most important risk
factor for glaucoma progression [6,7], accurate IOP measurement is critical for glaucoma
management. However, LRS changes the central corneal thickness (CCT) and corneal
curvature, which consequently affect IOP measured via Goldmann applanation tonometry
(GAT), [8,9] resulting in erroneous IOP measurements. Because of these inaccurate IOP
measurements, glaucoma progression may be more common in eyes with a history of LRS
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than in those without a history of LRS, and IOP management in glaucomatous eyes with a
history of LRS may require further investigation.
Despite these concerns, few studies have investigated the effects of IOP on glaucoma
progression in eyes with a history of LRS. Although one previous study reported risk
factors for glaucoma progression in eyes that had undergone LRS [10], the effects of IOP
measured during the follow-up period were not investigated. Therefore, in this study,
we aimed to investigate the effects of clinical variables, including IOP measurements, on
structural progression in glaucomatous eyes with a history of LRS and compare them
to age-matched glaucomatous eyes without a history of LRS. We used optical coherence
tomography (OCT) to investigate structural progression, as it is considered more sensitive
to the detection of progression in the early stages of the disease that may be not detected
via visual field (VF) tests [11–13].
2. Materials and Methods
This retrospective cohort study was approved by the Institutional Review Board of
Yongin Severance Hospital (9-2020-0105) and adhered to the tenets of the Declaration of
Helsinki. We retrospectively reviewed the medical records of all patients who visited the
glaucoma clinic at Severance Hospital from February 2011 to January 2020. The requirement
for informed consent was waived because of the retrospective study design, and all clinical
data were anonymised.
Inclusion criteria were as follows: an open-angle on gonioscopy, best-corrected visual
acuity >20/30, no medical history of systemic disease, and no history of anti-glaucoma
medication use before the initial clinic visit. At least eight IOP measurements using GAT
at regular clinic visits were required for inclusion. Patients with glaucoma who under-
went ophthalmic surgeries other than LRS (e.g., cataract surgery, vitrectomy, or glaucoma
surgery) were excluded. Patients who discontinued using anti-glaucoma medication dur-
ing the follow-up period(s) and those who used steroid or non-steroidal anti-inflammatory
eye drops were also excluded. To minimise the floor effect of OCT measurements [14], we
excluded eyes with a mean deviation (MD) of <−20 dB or peripapillary retinal nerve fibre
layer (RNFL) thickness of <60 µm. If both eyes were eligible for inclusion, one eye was
randomly selected.
All participants underwent complete ophthalmic examinations: measurements of
best-corrected visual acuity, IOP using GAT, CCT measurements using an ultrasonic
pachymeter (DGH-1000; DGH Technology, Inc., Frazer, PA, USA), slit-lamp biomicroscopy,
dilated fundus examination, colour disc photography (Carl Zeiss Meditec, Jena, Germany),
spectral-domain OCT (Cirrus HD-OCT, software v11.0; Carl Zeiss Meditec), axial length
measurements (IOL Master; Carl Zeiss Meditec), and VF tests (Humphrey Field Analyzer
II; Carl Zeiss Meditec).
The diagnosis of glaucoma was based on the characteristics of glaucomatous optic
disc change and RNFL defect with VF defect. VF defects had to satisfy at least two of the
Anderson criteria [15]. Two glaucoma specialists (S.Y.L. and K.L.) reviewed the medical
records of patients with glaucoma. In case of disagreements between these specialists, a
third glaucoma specialist (C.Y.K.) was consulted to verify the diagnosis.
IOP was measured at each follow-up visit in accordance with the standard procedure
of our institution [16]. IOP measurements during follow-up periods were averaged (mean
IOP), and the maximum IOP value (peak IOP) was extracted. To manage IOP fluctuations,
the standard deviation of all IOP values measured during the follow-up period was
calculated (IOP fluctuation). Adjustments of IOP were made using the following linear
formula: Corrected IOP= Measured IOP − (CCT − 545)/2.5 mm Hg [17].
The LRS group included individuals who underwent LRS surgery, including LASIK
and LASEK, at least 3 years before the initial visit to the clinic [16]. Participants with
myopia (refractive error <−0.5 D or axial length ≥24.0 mm) without a history of LRS and
younger than 60 years were categorised into the non-LRS group [16]. All patients with
LRS participated in the study when myopia was fully corrected by LRS, except those who
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experienced an IOP elevation after LRS. Because our preliminary data showed that the LRS
group was younger than the non-LRS group, we only included individuals younger than
60 years to minimise the effect of age on structural progression.
2.1. Optical Coherence Tomography and Guided Progression Analysis
OCT images of the peripapillary RNFL were obtained with an optic disc cube scan
using Cirrus HD-OCT. The optic disc cube scan produced an RNFL thickness map of
6 × 6 mm (200 × 200 pixels) in the area centred on the optic nerve head. Peripapillary
RNFL thickness was measured circularly with a diameter of 3.46 mm. At least five reliable
OCT scans from separate visits were required for inclusion in the study. All OCT scans
had a signal strength of ≥6. Scans with motion artefacts, poor centration, or missing
data were excluded. All scans were reviewed by glaucoma specialists (S.Y.L. and K.L.). If
peripapillary RNFL was measured inaccurately due to myopic disc morphology (optic disc
torsion or tilt), those scans were excluded from the analysis.
We evaluated the structural progression of the peripapillary RNFL using an event-
based algorithm provided by guided progression analysis. The guided progression analysis
algorithm compared the changes in peripapillary RNFL thickness at individual superpixels
(1 superpixel = 4 × 4 pixels) between two baseline thickness maps and the follow-up
thickness map. For the change to have been considered significant, a change of at least
20 adjacent superpixels must have been detected in the RNFL thickness maps. If a follow-
up OCT examination demonstrated a statistically significant difference in thickness that
exceeded the baseline test–retest variability, the superpixel was labelled yellow to indicate
a possible loss. If confirmed on a second follow-up OCT examination, it was labelled red to
indicate a probable loss. Structural progression was defined as the detection of “likely loss”
in the event analysis, and this change was observed at the most recent follow-up visit.
2.2. Statistical Analyses
Statistical analyses were performed using R software v3.6.3 (R Foundation for Statisti-
cal Computing, Vienna, Austria). Baseline clinical variables are presented as the mean ±
standard deviation. We used t-tests to compare variables between the non-LRS and LRS
groups and between stable eyes and eyes with structural progression in each group. The
chi-square test was used to compare categorical data. Hazard ratios (HRs) of potential
risk factors for structural progression were investigated using Cox regression analysis.
Variables with a p-value < 0.05 in the univariate analysis were considered significant and
were included in a multivariate Cox regression analysis. All tests reported p-values as
bilateral; those less than 0.05 were considered statistically significant.
3. Results
A total of 90 glaucomatous eyes of 90 individuals were included in our study. Among
them, 40 eyes had a history of LRS, and 50 age-matched eyes had no history of LRS.
All patients were treated with an anti-glaucoma medication. The mean age of the study
population was 42.5 ± 10.7 years. The mean baseline peripapillary RNFL thickness was
79.0 ± 10.7 µm, and the average of VF MD was −4.8 ± 4.5 dB. A summary of the other
variables is presented in Table 1.
The occurrence of structural progression was not different between the non-LRS and
LRS groups (Table 1). The baseline peripapillary RNFL thickness, VF MD, sex, and history
of hypertension and diabetes did not differ between the two groups (Table 1). However,
baseline IOP, mean IOP, disc haemorrhage (DH), and CCT were significantly different
between the two groups, although IOP fluctuation and peak IOP were not (Table 1).
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Table 1. Demographic characteristics.
Total Non-LRS LRS
p-Value
(n = 90) (n = 50) (n = 40)
Age (years) 42.5 ± 10.7 42.7 ± 12.0 42.2 ± 8.9 0.825
Sex (male/female) 44 (48.9%)/46 (51.1%) 25 (50.0%)/25 (50.0%) 19 (47.5%)/21 (52.5%) 0.981
Hypertension (Y/N) 11 (12.2%)/79 (87.8%) 4 (8.0%)/46 (92.0%) 7 (17.5%)/33 (82.5%) 0.297
Diabetes (Y/N) 4 (4.4%)/86 (95.6%) 2 (4.0%)/48 (96.0%) 2 (5.0%)/38 (95.0%) 0.999
Disc haemorrhage (Y/N) 18 (18.6%)/79 (81.4%) 13 (26.0%)/37 (74.0%) 3 (7.5%)/37 (92.5%) 0.045
Baseline RNFL thickness (µm) 79.0 ± 10.7 79.3 ± 10.2 78.6 ± 11.4 0.768
MD (decibel) −4.8 ± 4.5 −4.3 ± 4.4 −5.5 ± 4.5 0.191
Axial length (mm) 26.4 ± 1.1 26.0 ± 1.1 26.6 ± 1.1 0.051
Central corneal thickness (µm) 507.2 ± 50.2 539.4 ± 27.7 470.9 ± 44.9 <0.001
Baseline IOP (mmHg) 16.0 ± 3.3 16.6 ± 3.1 14.7 ± 3.5 0.020
Mean IOP (mmHg) 13.3 ± 2.5 14.3 ± 2.1 12.0 ± 2.4 <0.001
IOP fluctuation (mmHg) 1.9 ± 1.0 1.7 ± 0.6 2.1 ± 1.4 0.076
Peak IOP (mmHg) 16.8 ± 4.0 17.2 ± 2.8 16.2 ± 5.2 0.279
Adjusted baseline IOP (mmHg) 20.2 ± 3.4 21.0 ± 3.1 18.9 ± 3.5 0.014
Adjusted mean IOP (mmHg) 17.4 ± 2.6 18.5 ± 2.2 16.2 ± 2.4 <0.001
Adjusted Peak IOP (mmHg) 21.0 ± 4.1 21.4 ± 2.9 20.4 ± 5.2 0.267
Structural progression
(stable/progressed) 54 (60.0%)/36 (40.0%) 29 (58.0%)/21 (42.0%) 25 (62.5%)/15 (37.0%) 0.829
Follow-up period (months) 60.3 ± 18.2 58.4 ± 18.0 62.6 ± 18.6 0.287
Parameters are presented as the mean ± standard deviation or n (%). LRS: laser refractive surgery; Y: yes; N: no; RNFL: retinal nerve fibre
layer; MD: mean deviation; IOP: intraocular pressure. p-values were calculated using t-tests (comparison between the non-LRS and LRS
groups). Indicated in bold type, p < 0.05 indicates statistical significance.
In the non-LRS group, patients with glaucoma progression were younger and had
better MD than those without glaucoma progression. In the LRS group, patients with
glaucoma progression had a thicker baseline peripapillary RNFL and a higher mean IOP
and peak IOP than those without glaucoma progression (Table 2).
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(n = 29) (n = 21) (n = 25) (n = 15)
MD (dB) −5.9 ± 5.1 −2.1 ± 1.6 0.001 −6.4 ± 4.5 −4.0 ± 4.2 0.107
Axial length (mm) 25.8 ± 0.7 26.3 ± 1.3 0.255 26.7 ± 1.2 26.5 ± 1.1 0.746
Central corneal thickness (µm) 542.3 ± 26.6 535.1 ± 29.5 0.397 469.6 ± 46.7 473.3 ± 43.4 0.804
Baseline IOP (mmHg) 16.5 ± 3.4 16.8 ± 2.7 0.746 14.7 ± 3.6 14.8 ± 3.7 0.956
Mean IOP (mmHg) 14.1 ± 2.0 14.6 ± 2.3 0.400 11.2 ± 2.0 13.5 ± 2.5 0.014
IOP fluctuation (mmHg) 1.6 ± 0.4 1.8 ± 0.7 0.211 1.7 ± 0.9 2.7 ± 1.8 0.069
Peak IOP (mmHg) 16.9 ± 2.2 17.6 ± 3.4 0.404 14.8 ± 4.5 18.6 ± 5.6 0.023
Adjusted baseline IOP
(mmHg) 20.8 ± 3.4 21.3 ± 2.7 0.604 18.9 ± 3.6 18.9 ± 3.7 0.956
Adjusted mean IOP (mmHg) 18.3 ± 2.0 18.7 ± 2.4 0.537 15.4 ± 2.0 17.7 ± 2.5 0.002
Adjusted Peak IOP (mmHg) 21.2 ± 2.2 21.9 ± 3.6 0.477 19.0 ± 4.5 22.8 ± 5.6 0.023
The parameters are presented as the mean ± standard deviation or n (%). LRS: laser refractive surgery; Y: yes; N: no; RNFL: retinal nerve
fibre layer; MD: mean deviation; IOP: intraocular pressure. p-values were calculated using t-tests (comparison between stable eyes and
progressed eyes in each group). Indicated in bold type, p < 0.05 indicates statistical significance.
Cox regression results are shown in Tables 3 and 4. In the non-LRS group, young
age, history of DH, and better baseline MD were associated with glaucoma progression.
Multivariate Cox regression analysis revealed that age and history of DH were related
to structural progression (Table 3). In the LRS group, a history of DH and a larger IOP
fluctuation were associated with structural progression in the univariate and multivariate
Cox analyses (Table 4).
Table 3. Cox regression for the non-LRS group.
Univariate Multivariate
HR p-Value HR p-Value
Age (years) 0.935 (0.892–0.979) 0.004 0.921 (0.868–0.977) 0.007
Sex (male/female) 1.369 (0.573–3.269) 0.479
Hypertension (Y/N) 0.904 (0.208–3.929) 0.893
Diabetes (Y/N) 0.766 (0.099–5.902) 0.798
Disc haemorrhage (Y/N) 2.664 (1.053–6.742) 0.039 4.650 (1.402–15.416) 0.012
Baseline RNFL thickness (µm) 1.024 (0.989–1.061) 0.181
MD (decibel) 1.248 (1.049–1.486) 0.013 1.097 (0.929–1.295) 0.277
Axial length (mm) 0.901 (0.526–1.546) 0.706
Central corneal thickness (µm) 0.998 (0.980–1.017) 0.846
Baseline IOP (mmHg) 0.934 (0.808–1.079) 0.353
Mean IOP (mmHg) 0.983 (0.795–1.216) 0.875
IOP fluctuation (mmHg) 0.842 (0.391–1.811) 0.660
Peak IOP (mmHg) 0.950 (0.811–1.111) 0.520
Adjusted baseline IOP (mmHg) 0.961 (0.823–1.121) 0.611
Adjusted mean IOP (mmHg) 1.021 (0.827–1.262) 0.884
Adjusted Peak IOP (mmHg) 0.983 (0.845–1.145) 0.829
LRS: laser refractive surgery; HR: hazard ratio; Y: yes; N: no; RNFL: retinal nerve fibre layer; MD: mean deviation; IOP: intraocular pressure.
Indicated in bold type, p < 0.05 indicates statistical significance.
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Table 4. Cox regression for the LRS group.
Univariate Multivariate
HR p-Value HR p-Value
Age (years) 1.001 (0.942–1.065) 0.965
Sex (male/female) 1.006 (0.319–3.173) 0.992
Hypertension (Y/N) 1.339 (0.361–4.963) 0.662
Diabetes (Y/N) NA (0.000–Infinite) 0.999
Disc haemorrhage (Y/N) 6.144 (1.123–33.611) 0.036 8.666 (1.431–52.480) 0.019
Baseline RNFL thickness (µm) 1.037 (0.994–1.082) 0.090
MD (decibel) 1.023 (0.902–1.160) 0.723
Axial length (mm) 0.846 (0.480–1.490) 0.562
Central corneal thickness (µm) 1.000 (0.988–1.011) 0.938
Baseline IOP (mmHg) 1.041 (0.870–1.244) 0.662
Mean IOP (mmHg) 1.173 (0.961–1.432) 0.117
IOP fluctuation (mmHg) 1.357 (1.001–1.839) 0.050 1.452 (1.052–2.004) 0.023
Peak IOP (mmHg) 1.061 (0.969–1.162) 0.201
Adjusted baseline IOP (mmHg) 1.041 (0.870–1.244) 0.662
Adjusted mean IOP (mmHg) 1.173 (0.961–1.432) 0.117
Adjusted Peak IOP (mmHg) 1.061 (0.969–1.162) 0.201
LRS: laser refractive surgery, HR: hazard ratio; Y: yes; N: no; RNFL: retinal nerve fibre layer; MD: mean deviation; NA: not available; IOP:
intraocular pressure. Indicated in bold type, p < 0.05 indicates statistical significance.
4. Discussion
In this study, we investigated the risk factors for structural progression in glaucoma-
tous eyes with and without a history of LRS. Although the occurrence of progression did
not significantly differ between the non-LRS and LRS groups, risk factors differed between
the two groups. According to the results of the multivariate Cox regression analysis, DH
was related to structural progression, regardless of a history of LRS. Long-term IOP fluctu-
ation was associated with structural progression only in the LRS group, whereas age was
associated with structural progression only in the non-LRS group.
Cox regression analysis revealed that IOP fluctuation was associated with struc-
tural progression in the LRS group, whereas mean IOP and peak IOP were not. The
relationship between long-term IOP fluctuation and glaucoma progression has been
controversial [18–21]. Our results are consistent with those of the Advanced Glaucoma
Intervention Study (AGIS), which reported that long-term IOP fluctuation is the most
critical risk factor for VF progression in glaucoma [20]. A large retrospective study of
patients treated for primary open-angle glaucoma or primary angle-closure glaucoma
also reported that IOP fluctuation is significantly associated with disease progression [19].
However, the Early Manifest Glaucoma Trial (EMGT) reported that mean IOP is related to
disease progression, while IOP fluctuation is not [18]. These conflicting results may be due
to the differences in the mean IOP of the study population. The participants of the EMGT,
including untreated patients with early glaucoma, had a mean IOP of 20.7 ± 4.1 mmHg,
which was greater than that in our study (13.4 ± 2.4 mmHg) and the AGIS. These results
imply that a threshold mean IOP is required to induce glaucoma progression. The mean
IOP of our study participants was controlled to be less than 15 mmHg; thus, the effect of
the mean IOP on glaucoma progression may be insignificant. Our results do not suggest
that the mean IOP is not related to structural progression but that when the patient’s mean
IOP is well controlled, structural progression could occur due to IOP fluctuations.
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Interestingly, IOP fluctuation was a risk factor for structural progression only in the
LRS group, even though it did not significantly differ between the two groups. While
the relationship between long-term IOP fluctuation and glaucoma progression remains
controversial [18–22], a recent study reported that long-term IOP fluctuation could be a
significant risk factor for structural progression in medically treated glaucoma eyes with a
mean IOP of ≤15 mmHg [14]. Since the mean IOP of our participants was 13.3 mmHg, IOP
fluctuation could show the association with glaucoma progression. Our result implies that
IOP fluctuation, as with IOP measurements, may be underestimated in the LRS group. We
previously reported on the difference between IOP measured via GAT and IOP measured
via dynamic contour tonometry (DCT) in LRS eyes. In that study, the fluctuation of
IOP measured via DCT was 1.93 mmHg, which was higher than that measured via GAT
(1.77 mmHg). Considering that DCT measurements are known to better reflect the actual
IOP [23], the actual IOP fluctuation in the LRS group is assumed to be larger than that
calculated from GAT measurements. Moreover, our results suggest that IOP fluctuation
could be closely related to a structural progression in myopic glaucomatous eyes. A recent
study has reported that long-term IOP fluctuation is more significantly related to VF
progression in myopic normal-tension glaucoma (NTG) eyes than in non-myopic NTG
eyes [24]. Myopic eyes are known to have a thinner lamina cribrosa than non-myopic
eyes [25]; thus, they may be more vulnerable to the same degree of IOP fluctuation than
non-myopic eyes. In addition, recent studies reported that 24-h IOP fluctuation was
associated with VF progression and axial length. Therefore, further studies that include
24 h IOP profile analysis are recommended.
DH was reaffirmed as a well-known risk factor for NTG progression [26] in this
study. We included patients with glaucoma, regardless of baseline IOP. The mean baseline
IOP of our participants was 16.0 ± 3.3 mmHg, suggesting that most participants were
patients with NTG. DH has been considered to indicate progressive structural damage
in glaucomatous eyes. That is, optic disc changes, new RNFL defects, and enlargement
of pre-existing RNFL defects are more likely to occur after DH [26–28]. These results are
consistent with our finding that DH is a risk factor for structural progression. Although the
finding that DH is closely related to structural progression has been reported consistently
in numerous studies, the reported range of HR values is large. In our study, the HRs
of DH for structural progression were 4.650 in the non-LRS group and 8.666 in the LRS
group, similar to those in a previous study that reported HRs of 15.533 in median NTG
eyes and 7.596 in conventional NTG eyes [2]. In contrast, Kim et al. [29] reported that
the HR of DH was 1.718 when analysing 127 patients with pre-perimetric open-angle
glaucoma. These different results may be attributable to the different characteristics of
the participants. Lee et al. [2] reported that DH is a risk factor in conventional NTG eyes
but not in conventional high-tension glaucoma (HTG) eyes. When the study participants
were divided according to the median IOP, the HR of DH in median NTG eyes (median
IOP ≤15 mmHg) was 13.926, which was higher than the HR (7.572) in median HTG eyes
(median IOP >15 mmHg). Overall, these results indicate that the relationship between DH
and glaucoma progression may be stronger in NTG eyes.
One of the unexpected findings of our study was the relationship between younger
age and glaucoma progression found in the non-LRS group. According to previous studies,
older age increases the risk of glaucoma progression [6,30]. These contradictory results
may be attributable to treatment selection bias. Clinicians who know that glaucoma can
progress faster in older patients may attempt to control patients’ IOP more strictly. In our
study, the mean IOP in the non-LRS group tended to decrease with age (data now shown).
In other words, the mean IOP of younger patients in the non-LRS group was relatively high,
which may have enabled the detection of glaucoma progression in these young patients.
CCT was not associated with structural progression in our study, but previous studies
have reported an association between CCT and glaucoma progression [31,32]. The results
of the Ocular Hypertension Treatment Study (OHTS) demonstrated that CCT is an impor-
tant risk factor for glaucoma progression in patients with ocular hypertension [32], but the
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EMGT study failed to find a significant association between CCT and glaucoma progres-
sion [33]. These results may be explained by differences in baseline IOP between studies.
Based on the OHTS results, the effect of CCT on glaucoma progression was stronger in
eyes with IOP above 25.75 mmHg, suggesting that the effect of CCT on glaucoma progres-
sion is stronger in those with higher IOP. In our study, the mean IOP of the participants
(13.5 ± 2.3 mmHg) was similar to that in the EMGT study and lower than that in the OHTS;
thus, a significant association between CCT and glaucoma progression may not have been
observed. Several recent studies have reported corneal biomechanical variables besides
CCT (e.g., low corneal hysteresis) that are associated with glaucoma progression [34,35];
therefore, further study regarding this relationship is necessary.
This study has several limitations. First, this study included a small number of
patients. To ensure sufficient statistical power, a previous study was referenced [14], and
the statistical power was confirmed through a post hoc analysis. The required sample
size was at least 26 when calculated using mean IOP and structural progression in the
LRS group. However, some variables may need to be analysed with a larger sample size
to have enough statistical power to show a significant effect, especially in the non-LRS
group. Second, we analysed structural progression only, without considering functional
progression. Because OCT is not sensitive for detecting progression in patients with
advanced glaucoma, eyes with advanced glaucoma were excluded from the analyses.
Therefore, the risk factors identified in this study may not apply to advanced glaucoma.
Additionally, only peripapillary RNFL was analysed to detect structural progression in
this study. One recent study reported that monitoring of macular ganglion cell-inner
plexiform layer measurements could be effective for predicting glaucoma progression in
high myopia [36]. Therefore, we believe that further studies that include macular ganglion
cell-inner plexiform layer analysis are needed. Third, because the baseline IOP of the
study participants was in the NTG range, the results of our study may not be applicable to
patients with open-angle glaucoma whose baseline IOP is not within the normal range. Our
finding that IOP fluctuation, not mean or peak IOP, was significantly related to structural
progression may be limited to patients with NTG. Therefore, further studies including
patients with open-angle glaucoma with a higher baseline IOP are necessary. Forth, due
to the retrospective nature of this study, IOP was measured by different examiners. The
accuracy of IOP measurements may be affected by the inter-examiner differences. Despite
this limitation, the IOP of the participants in this study were measured using a consistent
and standardised method, so inter-examiner differences for IOP measurements were
considered controlled.
5. Conclusions
Risk factors for structural progression of open-angle glaucoma differed between
the LRS and non-LRS groups. IOP fluctuation and DH were significant risk factors in
glaucomatous eyes with a history of LRS. These results suggest that when managing
glaucoma patients with a history of LRS, IOP fluctuation should be minimised, and more
aggressive treatment should be considered if DH is found.
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